Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Auxilium Pharmaceuticals

Related AUXL
UPDATE: Jefferies Reiterates On Auxilium Pharmaceuticals, Inc. As Restructuring Realigns Costs With Commercial Opportunities
Auxilium Pharmaceuticals, Inc. Announces Corporate Restructuring Designed To Streamline Operations, Cutting 30% Of Jobs

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Auxilium Pharmaceuticals (NASDAQ: AUXL), and raised its price target from $28.00 to $30.00.

BofA Merrill Lynch noted, “We view the risk/reward for AUXL shares as positive, as we believe that Xiaflex has significant sales potential for Dupuytren's disease and could be a long-lived asset. Given the advantages of Xiaflex over surgery, we believe that Dupuytren's and follow-on indication Peyronie's could represent $1bn+ market opportunities with limited competition. We also like that Xiaflex is a biologic, which will reduce generic risk exposure and improve long-term revenue and earnings visibility.”

Auxilium Pharmaceuticals closed on Tuesday at $26.94.

Latest Ratings for AUXL

Sep 2014RF LaffertyUpgradesHoldBuy
Sep 2014JefferiesMaintainsBuy
Jun 2014Aegis CapitalInitiates Coverage onBuy

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters